摘要 目的 探讨替吉奥并吉西他滨治疗晚期胰腺癌的临床效果。 方法 以2013年1月—2016年1月于我院住院的晚期胰腺癌病人94例作为研究对象，随机分为对照组和研究组，其中对照组47例，采用吉西他滨治疗，研究组47例，采用替吉奥并吉西他滨治疗。比较两组病人的治疗效果、临床受益反应（CBR）、不良反应以及病人生存情况。 结果 研究组治疗总有效率和CBR明显高于对照组（χ2=4.41、6.13，P＜0.05）。两组病人不良反应发生率比较，差异无显著性（P＞0.05）。两组病人5个月生存率比较差异无显著性（P＞0.05）；研究组9、12个月生存率明显高于对照组（χ2=10.36、8.24，P＜0.05）。 结论 替吉奥并吉西他滨可提高晚期胰腺癌病人治疗效果，明显延长病人生存周期，但不良反应无明显增加，值得在临床推广应用。 Abstract：Objective To investigate the clinical efficacy of S-1 plus gemcitabine in the treatment of advanced pancreatic carcinoma. Methods A total of 94 patients with advanced pancreatic carcinoma who were hospitalized in our hospital from January 2013 to January 2016 were randomly divided into control group and study group. The 47 from the control group were treated with gemcitabine, while the other 47 from the study group were treated with S-1 plus gemcitabine. Treatment outcome, clinical benefit response (CBR), adverse events, and patient survival were compared between the two groups. Results Compared with the control group, the study group showed significantly higher overall response rate and CBR (χ2=4.41,6.13,P<0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05). There was no significant difference in 5-month survival rate between the two groups (P>0.05). Compared with the control group, the study group had significantly higher 9-month and 12-month survival rates (χ2=10.36,8.24,P<0.05). Conclusion S-1 plus gemcitabine can improve the treatment outcome of patients with advanced pancreatic carcinoma and significantly prolong their survival, but without significantly increasing adverse events, so it holds promise for clinical application
